Posts by Alan Smythe

ShiraTronics, Inc., a clinical-stage medical device company focused on developing novel neuromodulation therapies for chronic migraine, today announced compelling 12-month follow-up data from its RELIEV-CM Pilot Study. The findings demonstrate sustained reductions in headache frequency and severity, continued improvement in migraine-specific quality of life, and a consistently favorable safety profile, underscoring the long-term potential of the company’s investigational, fully implantable Migraine Therapy System.

Shiratronics: Addressing Chronic Migraine Head-On

ShiraTronics, inspired to improve upon an off-label treatment, a Minneapolis-based start-up offers chronic migraine patients a dedicated solution for individuals impacted by this disabling condition.

MedTech STRATEGIST JULY-AUGUST 2025 | Vol. 12, No. 7 (Reprinted with permission)

First Implants of Innovative Device Completed in the United States and Australia

ShiraTronics, a clinical-stage innovator in neuromodulation technology, today announced the initiation of its U.S. Food and Drug Administration (FDA) – approved Investigation Device Exemption (IDE) pivotal trial, the RELIEV-CM2 Clinical Study. The first implants of ShiraTronics neuromodulation therapy for Chronic Migraine have been completed in the United States and Australia, marking a new chapter in the company’s efforts to develop innovative solutions for individuals impacted by this disabling condition.